{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:45:53Z","timestamp":1770417953898,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36317-4","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:55:22Z","timestamp":1768571722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virtual screening of novel alkaloids as potent inhibitors for G2032R-mutant ROS1 kinase in non-small-cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Shu-Chi","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-An","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Ta","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"36317_CR1","doi-asserted-by":"crossref","unstructured":"Rod, N. H. et al. Cancer burden among adolescents and young adults in relation to childhood adversity: a nationwide life-course cohort study of 1.2 million individuals. Lancet Reg. Health Eur 27 (2023).","DOI":"10.1016\/j.lanepe.2023.100588"},{"key":"36317_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"36317_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min, H. Y. & Lee, H. Y. Molecular targeted therapy for anticancer treatment. Exp. Mol. Med. 54, 1670\u20131694 (2022).","journal-title":"Exp. Mol. Med."},{"key":"36317_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-statistics-030718-105251","volume":"6","author":"MR Kosorok","year":"2019","unstructured":"Kosorok, M. R. & Laber, E. B. Precision medicine. Annu. Rev. Stat. Appl. 6, 263\u2013286 (2019).","journal-title":"Annu. Rev. Stat. Appl."},{"key":"36317_CR5","doi-asserted-by":"publisher","first-page":"e70853","DOI":"10.1002\/cam4.70853","volume":"14","author":"J Farhat","year":"2025","unstructured":"Farhat, J., Alzyoud, L., AlWahsh, M., Acharjee, A. & Al-Omari, B. Advancing precision medicine: the role of genetic testing and sequencing technologies in identifying biological markers for rare cancers. Cancer Med. 14, e70853 (2025).","journal-title":"Cancer Med."},{"key":"36317_CR6","doi-asserted-by":"publisher","first-page":"1238093","DOI":"10.3389\/fmolb.2023.1238093","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang, X., Tang, Z., Li, J., Jiang, J. & Liu, Y. Progress of non-small-cell lung cancer with ROS1 rearrangement. Front. Mol. Biosci. 10, 1238093 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"36317_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863\u2013870 (2012).","journal-title":"J. Clin. Oncol."},{"key":"36317_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gcc.10207","volume":"37","author":"A Charest","year":"2003","unstructured":"Charest, A. et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial Del (6)(q21q21). Genes Chromosomes Cancer. 37, 58\u201371 (2003).","journal-title":"Genes Chromosomes Cancer"},{"key":"36317_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/cncr.27967","volume":"119","author":"J Lee","year":"2013","unstructured":"Lee, J. et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119, 1627\u20131635 (2013).","journal-title":"Cancer"},{"key":"36317_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/curroncol29020057","volume":"29","author":"S Gendarme","year":"2022","unstructured":"Gendarme, S., Bylicki, O., Chouaid, C. & Guisier, F. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr. Oncol. 29, 641\u2013658 (2022).","journal-title":"Curr. Oncol."},{"key":"36317_CR11","doi-asserted-by":"publisher","first-page":"e033427","DOI":"10.1136\/bmjopen-2019-033427","volume":"10","author":"JC Hsu","year":"2020","unstructured":"Hsu, J. C. et al. Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open. 10, e033427. https:\/\/doi.org\/10.1136\/bmjopen-2019-033427 (2020).","journal-title":"BMJ Open."},{"key":"36317_CR12","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 93, 102693 (2024).","journal-title":"Cancer Epidemiol."},{"key":"36317_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon, A. et al. Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer. N Engl. J. Med. 390, 118\u2013131 (2024).","journal-title":"N Engl. J. Med."},{"key":"36317_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","volume":"121","author":"R Roskoski Jr","year":"2017","unstructured":"Roskoski, R. Jr ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol. Res. 121, 202\u2013212 (2017).","journal-title":"Pharmacol. Res."},{"key":"36317_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/cryst14020106","volume":"14","author":"JF Vilach\u00e3","year":"2024","unstructured":"Vilach\u00e3, J. F., Wassenaar, T. A. & Marrink, S. J. Structural aspects of the ROS1 kinase domain and oncogenic mutations. Crystals 14, 106 (2024).","journal-title":"Crystals"},{"key":"36317_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","volume":"469","author":"L Bubendorf","year":"2016","unstructured":"Bubendorf, L. et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 469, 489\u2013503 (2016).","journal-title":"Virchows Arch."},{"key":"36317_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217322","volume":"2016","author":"E Zhong","year":"2016","unstructured":"Zhong, E. & Huang, H. Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance. BMJ Case Rep. 2016, bcr2016217322. https:\/\/doi.org\/10.1136\/bcr-2016-217322 (2016).","journal-title":"BMJ Case Rep."},{"key":"36317_CR18","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","volume":"10","author":"R Katayama","year":"2019","unstructured":"Katayama, R. et al. The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes Crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat. Commun. 10, 3604 (2019).","journal-title":"Nat. Commun."},{"key":"36317_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41698-024-00663-1","volume":"8","author":"R Thawani","year":"2024","unstructured":"Thawani, R. et al. TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. NPJ Precis Oncol. 8, 175 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"36317_CR20","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.esmoop.2022.100418","volume":"7","author":"N Girard","year":"2022","unstructured":"Girard, N. et al. Lorlatinib for advanced ROS1\u2009+\u2009non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. ESMO open. 7, 100418 (2022).","journal-title":"ESMO open."},{"key":"36317_CR21","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.3390\/curroncol29090520","volume":"29","author":"B J\u00f3ri","year":"2022","unstructured":"J\u00f3ri, B. et al. Acquired G2032R resistance mutation in ROS1 to lorlatinib therapy detected with liquid biopsy. Curr. Oncol. 29, 6628\u20136634 (2022).","journal-title":"Curr. Oncol."},{"key":"36317_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/diagnostics14010048","volume":"14","author":"L Fabbri","year":"2023","unstructured":"Fabbri, L. et al. From development to place in therapy of lorlatinib for the treatment of ALK and ROS1 rearranged non-small cell lung cancer (NSCLC). Diagnostics 14, 48 (2023).","journal-title":"Diagnostics"},{"key":"36317_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.30574\/gscbps.2019.6.1.0163","volume":"6","author":"KZM Adibah","year":"2019","unstructured":"Adibah, K. Z. M. & Azzreena, M. A. Plant toxins: alkaloids and their toxicities. GSC biol. pharm. sci. 6, 21\u201329 (2019).","journal-title":"GSC biol. pharm. sci."},{"key":"36317_CR24","doi-asserted-by":"publisher","first-page":"12562","DOI":"10.1039\/c003419c","volume":"12","author":"J Qian","year":"2010","unstructured":"Qian, J. & Brouwer, A. M. Excited state proton transfer in the Cinchona alkaloid cupreidine. Phys. Chem. Chem. Phys. 12, 12562\u201312569 (2010).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"36317_CR25","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.3390\/molecules28145578","volume":"28","author":"K Olofinsan","year":"2023","unstructured":"Olofinsan, K., Abrahamse, H. & George, B. P. Therapeutic role of alkaloids and alkaloid derivatives in cancer management. Molecules 28, 5578 (2023).","journal-title":"Molecules"},{"key":"36317_CR26","first-page":"1","volume":"1","author":"N Bribi","year":"2018","unstructured":"Bribi, N. Pharmacological activity of alkaloids: a review. Asian J. Bot. 1, 1\u20136 (2018).","journal-title":"Asian J. Bot."},{"key":"36317_CR27","doi-asserted-by":"publisher","first-page":"1283784","DOI":"10.3389\/fphar.2023.1283784","volume":"14","author":"Y Cai","year":"2023","unstructured":"Cai, Y. et al. Efficacy and underlying mechanisms of Berberine against lipid metabolic diseases: a review. Front. Pharmacol. 14, 1283784 (2023).","journal-title":"Front. Pharmacol."},{"key":"36317_CR28","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pathogens10091120","volume":"10","author":"I Renard","year":"2021","unstructured":"Renard, I. & Ben Mamoun, C. Treatment of human babesiosis: then and now. Pathogens 10, 1120 (2021).","journal-title":"Pathogens"},{"key":"36317_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4269\/ajtmh.16-0138","volume":"95","author":"GD Shanks","year":"2016","unstructured":"Shanks, G. D. Historical review: problematic malaria prophylaxis with quinine. Am. J. Trop. Med. 95, 269 (2016).","journal-title":"Am. J. Trop. Med."},{"key":"36317_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","volume":"13","author":"A Banyal","year":"2023","unstructured":"Banyal, A. et al. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech. 13, 211 (2023).","journal-title":"3 Biotech."},{"key":"36317_CR31","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","volume":"13","author":"PC Agu","year":"2023","unstructured":"Agu, P. C. et al. Molecular Docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci. Rep. 13, 13398 (2023).","journal-title":"Sci. Rep."},{"key":"36317_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44386-024-00001-2","volume":"1","author":"H Wei","year":"2024","unstructured":"Wei, H. & McCammon, J. A. Structure and dynamics in drug discovery. NPJ Drug Discov. 1, 1 (2024).","journal-title":"NPJ Drug Discov"},{"key":"36317_CR33","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/molecules26082114","volume":"26","author":"S Parate","year":"2021","unstructured":"Parate, S., Kumar, V., Hong, J. C. & Lee, K. W. Identification of flavonoids as putative ROS-1 kinase inhibitors using pharmacophore modeling for NSCLC therapeutics. Molecules 26, 2114 (2021).","journal-title":"Molecules"},{"key":"36317_CR34","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2. 0: new Docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"36317_CR35","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.jtho.2017.11.127","volume":"13","author":"LE Raez","year":"2018","unstructured":"Raez, L. E., Manca, P., Rolfo, C. & Singh, V. ROS-1 rearrangements in Circulating tumor cells. J. Thorac. Oncol. 13, e71\u2013e72 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"36317_CR36","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T. et al. First-line lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N Engl. J. Med. 383, 2018\u20132029 (2020).","journal-title":"N Engl. J. Med."},{"key":"36317_CR37","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.3390\/molecules26071836","volume":"26","author":"M Heinrich","year":"2021","unstructured":"Heinrich, M., Mah, J. & Amirkia, V. Alkaloids used as medicines: structural phytochemistry Meets biodiversity\u2014An update and forward look. Molecules 26, 1836 (2021).","journal-title":"Molecules"},{"key":"36317_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/md20080026","volume":"6","author":"D Baunb\u00e6k","year":"2008","unstructured":"Baunb\u00e6k, D. et al. Anticancer alkaloid lamellarins inhibit protein kinases. Mar. Drugs. 6, 514\u2013527 (2008).","journal-title":"Mar. Drugs"},{"key":"36317_CR39","first-page":"795","volume":"25","author":"D Xu","year":"1990","unstructured":"Xu, D. et al. Isolation and identification of Yibeinoside A. Acta Pharm. Sin. 25, 795\u2013797 (1990).","journal-title":"Acta Pharm. Sin"},{"key":"36317_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/0975-9476.96523","volume":"3","author":"R Bhati","year":"2012","unstructured":"Bhati, R., Singh, A., Saharan, V. A., Ram, V. & Bhandari, A. Strychnos nux-vomica seeds: pharmacognostical standardization, extraction, and antidiabetic activity. J. Ayurveda Integr. Med. 3, 80 (2012).","journal-title":"J. Ayurveda Integr. Med."},{"key":"36317_CR41","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.matpr.2021.09.189","volume":"48","author":"A Rajput","year":"2022","unstructured":"Rajput, A., Sharma, R. & Bharti, R. Pharmacological activities and toxicities of alkaloids on human health. Mater. Today Proc. 48, 1407\u20131415 (2022).","journal-title":"Mater. Today Proc."},{"key":"36317_CR42","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer, T. M. et al. Clinical management of adverse events associated with lorlatinib. Oncologist 24, 1103\u20131110 (2019).","journal-title":"Oncologist"},{"key":"36317_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1006\/jmbi.2000.4301","volume":"305","author":"T Steiner","year":"2001","unstructured":"Steiner, T. & Koellner, G. Hydrogen bonds with \u03c0-acceptors in proteins: frequencies and role in stabilizing local 3D structures. J. Mol. Biol. 305, 535\u2013557 (2001).","journal-title":"J. Mol. Biol."},{"key":"36317_CR44","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","volume":"60","author":"H Guterres","year":"2020","unstructured":"Guterres, H. & Im, W. Improving protein-ligand Docking results with high-throughput molecular dynamics simulations. J. Chem. Inf. Model. 60, 2189\u20132198 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"36317_CR45","doi-asserted-by":"publisher","first-page":"1178228","DOI":"10.1155\/2022\/1178228","volume":"2022","author":"JF Fatriansyah","year":"2022","unstructured":"Fatriansyah, J. F. et al. Molecular dynamics simulation of ligands from Anredera cordifolia (Binahong) to the main protease (Mpro) of SARS-CoV-2. J. Trop. Med. 2022, 1178228 (2022).","journal-title":"J. Trop. Med."},{"key":"36317_CR46","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3390\/ijms23031771","volume":"23","author":"S Rampogu","year":"2022","unstructured":"Rampogu, S., Lee, G., Park, J. S., Lee, K. W. & Kim, M. O. Molecular Docking and molecular dynamics simulations discover Curcumin analogue as a plausible dual inhibitor for SARS-CoV-2. Int. J. Mol. Sci. 23, 1771 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"36317_CR47","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.sjbs.2023.103753","volume":"30","author":"ZK Bagewadi","year":"2023","unstructured":"Bagewadi, Z. K. et al. Molecular dynamics and simulation analysis against superoxide dismutase (SOD) target of micrococcus luteus with secondary metabolites from Bacillus licheniformis recognized by genome mining approach. Saudi J. Biol. Sci. 30, 103753 (2023).","journal-title":"Saudi J. Biol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36317-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:03:59Z","timestamp":1770375839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36317-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5342"}}